An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib (GSK1120212) in Subjects with Relapsed or Refractory Leukemias.

Trial Profile

An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib (GSK1120212) in Subjects with Relapsed or Refractory Leukemias.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Trametinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute nonlymphocytic leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by M.D. Anderson Cancer Center record.
    • 06 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top